Intelligence Β· Clinical Pipeline

Axsome Therapeutics Pipeline

All ClinicalTrials.gov programs at Axsome Therapeutics β€” phase, modality, and trial IDs.

Programs
18

Quick answer

Axsome Therapeutics has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. AXS-02

    Axsome Therapeutics

    Osteoarthritis, Knee

    phase 3 small molecule active

    1 trial
  2. AXS-02 (oral zoledronate)

    Axsome Therapeutics

    Complex Regional Pain Syndrome

    phase 3 small molecule active

    1 trial
  3. AXS-05

    Axsome Therapeutics

    Treatment Resistant Major Depressive Disorder

    phase 3 small molecule completed

    1 trial
  4. AXS-05

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    3 trials
  5. AXS-05

    Axsome Therapeutics

    Depression

    phase 3 small molecule completed

    1 trial
  6. AXS-05 (dextromethorphan and bupropion) oral tablets

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial
  7. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    2 trials
  8. AXS-07

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial
  9. AXS-07 (MoSEIC meloxicam and rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    2 trials
  10. AXS-07 (meloxicam-rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial
  11. AXS-12 (Reboxetine)

    Axsome Therapeutics

    Narcolepsy

    phase 3 small molecule completed

    3 trials
  12. AXS-14 (Esreboxetine)

    Axsome Therapeutics

    Fibromyalgia

    phase 3 small molecule active

    1 trial
  13. Solriamfetol 150 MG

    Axsome Therapeutics

    Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

    phase 3 small molecule active

    1 trial
  14. Solriamfetol 150 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial
  15. Solriamfetol 150 mg

    Axsome Therapeutics

    ADHD

    phase 3 small molecule completed

    1 trial
  16. Solriamfetol 150 mg

    Axsome Therapeutics

    Excessive Sleepiness

    phase 3 small molecule active

    1 trial
  17. Solriamfetol 300 mg

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial
  18. Solriamfetol 75mg, 150 mg, or 300 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Axsome Therapeutics have?

18 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs